CSB 2.008 Note
961.16 (3) (zx) Thiafentanil.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2016 No. 730, eff. 10-3-16;
CR 17-007: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.008 Note
CSB 2.45 Addition of AB-FUBINACA and ADB-PINACA to schedule I. Section
961.14 (4) (tb) 32. and
33., Stats., is created to read:
CSB 2.008 Note
961.14 (4) (tb) 32. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as AB-FUBINACA.
33. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as ADB-PINACA.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2016 No. 730, eff. 10-10-16;
CR 17-008: cr.
Register July 2017 No. 739, eff. 8-1-17.
CSB 2.008 Note
CSB 2.46 Addition of acetyl fentanyl to schedule I. Section
961.14 (2) (ae), Stats., is created to read:
CSB 2.008 Note
961.14 (2) (ae) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2016 No. 731, eff. 11-21-16;
CR 17-021: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.008 Note
CSB 2.47 Addition of AH-7921 to schedule I. Section
961.14 (2) (aj), Stats., is created to read:
CSB 2.008 Note
961.14 (2) (aj) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide).
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2016 No. 731, eff. 11-21-16;
CR 17-023: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.008 Note
CSB 2.48 Addition of eluxadoline to schedule IV. Section
961.20 (4) (cm), Stats., is created to read:
CSB 2.008 Note
961.20 (4) (cm) Eluxadoline, including any of its isomers, and salts of isomers.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2016 No. 731, eff. 11-21-16;
CR 17-022: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.008 Note
CSB 2.49 Addition of U-47700 to schedule I. Section
961.14 (2) (z), Stats., is created to read:
CSB 2.008 Note
961.14 (2) (z) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide).
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2016 No. 732, eff. 12-19-16;
CR 17-020: cr.
Register November 2017 No. 743, eff. 12-1-17.
CSB 2.008 Note
CSB 2.50 Addition of AB-CHMINACA, AB-PINACA and THJ-2201 to schedule I. Section
961.14 (4) (tb) 34.,
35., and
36., Stats., are created to read:
CSB 2.008 Note
961.14 (4) (tb) 34. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as AB-CHMINACA.
CSB 2.008 Note
35. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as AB-PINACA).
CSB 2.008 Note
36. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, commonly known as THJ-2201.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2017 No. 736, eff. 3-27-17; correction in (intro.) made under s.
35.17, Stats.,
Register April 2017 No. 736;
CR 17-085: cr.
Register October 2018 No. 754, eff. 11-1-18; correction in (intro.) made under s.
35.17, Stats.,
Register October 2018 No. 754.
CSB 2.008 Note
CSB 2.51 Addition of MAB-CHMINACA to schedule I. Section
961.14 (4) (tb) 37., Stats., is created to read:
CSB 2.008 Note
961.14 (4) (tb) 37. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as MAB-CHMINACA or ADB-CHMINACA.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2017 No. 736, eff. 3-27-17;
CR 17-086: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.008 Note
CSB 2.52 Addition of 4-MePPP and a-PBP to schedule I. Section
961.14 (7) (L) 32. and
33., Stats., is created to read:
CSB 2.008 Note
961.14 (7) (L) 32. 4-methyl-alpha-pyrrolidinopropiophenone, commonly known as 4-MePPP.
CSB 2.008 Note
33. Alpha-pyrrolidinobutiophenone, commonly known as a-PBP.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2017 No. 736, eff. 4-10-17;
CR 17-087: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.008 Note
CSB 2.53 Scheduling of acryl fentanyl. Section
961.14 (2) (ai), Stats., is created to read:
CSB 2.008 Note
961.14 (2) (ai) Acryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-2-propenamide);
CSB 2.008 Note Section 961.14 (2) (ai), Stats., was renumbered to s. 961.14 (2) (nd) 3. by
2017 Wis. Act 60.
CSB 2.008 History
History:
EmR1710: emerg. cr., eff. 5-2-17;
CR 17-040: cr.
Register November 2017 No. 743, eff. 12-1-17; correction made under s.
35.17, Stats.,
Register November 2017 No. 743.
CSB 2.008 Note
CSB 2.54 Addition of oral solutions containing dronabinol to schedule II. Section
961.16 (10), Stats., is created to read:
CSB 2.008 Note
961.16 (10) (a) Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution in a drug product approved by the U.S. food and drug administration.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2017 No. 737, eff. 5-15-17;
CR 18-055: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.008 Note
CSB 2.55 Addition of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I. Section
961.14 (4) (tb) 38.,
39.,
40.,
41., and
42., Stats., is created to read:
CSB 2.008 Note
961.14 (4) (tb) 38. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB.
CSB 2.008 Note
39. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB.
CSB 2.008 Note
40. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as ADB-FUBINACA.
CSB 2.008 Note
41. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as MDMB-CHMICA.
CSB 2.008 Note
42. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register May 2017 No. 737, eff. 5-15-17;
CR 17-088: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.008 Note
CSB 2.56 Addition of 4-fluoroisobutyryl fentanyl to schedule I. Section
961.14 (2) (nd) 10t., Stats., is created to read:
CSB 2.008 Note
961.14 (2) (nd) 10t. 4-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register June 2017 No. 738, eff. 6-12-17;
CR 17-089: cr.
Register October 2018 No. 754, eff. 11-1-18.
CSB 2.008 Note
CSB 2.57 Scheduling of cyclopropyl fentanyl. Section
961.14 (2) (nd) 10d., Stats., is created to read:
CSB 2.008 Note
961.14 (2) (nd) 10d. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
CSB 2.008 History
History:
EmR 1716: emerg. cr. eff. 9-8-17; CR
17-0785: cr.
Register July 2018 No. 751, eff. 8-1-18; corrections made under s.
35.17, Stats.,
Register July 2018 No. 751.
CSB 2.008 Note
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register November 2017 No. 743, eff. 11-20-17;
CR 18-024: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.008 Note
CSB 2.59 Addition of ortho-fluorofentanyl to schedule I. Section
961.14 (2) (nd) 16m., Stats., is created to read:
CSB 2.008 Note
961.14 (2) (nd) 16m. Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2017 No. 744, eff. 12-4-17; correction made under s.
35.17, Stats.,
Register December 2017 No. 744;
CR 18-023: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.008 Note
CSB 2.60 Addition of FUB-AMB to schedule I. Section
961.14 (4) (tb) 43., Stats., is created to read:
CSB 2.008 Note
961.14 (4) (tb) 43. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as FUB-AMB, MMB-FUBINACA or AMB-FUBINACA.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register December 2017 No. 744, eff. 12-11-17; correction made under s.
35.17, Stats.,
Register December 2017 No. 744;
CR 18-022: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.008 Note
CSB 2.61 Addition of MT-45 to schedule I. Section
961.14 (2) (rk), Stats., is created to read:
CSB 2.008 Note
961.14 (2) (rk) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register January 2018 No. 745, eff. 1-22-18; correction made under s.
35.17, Stats.,
Register January 2018 No. 745;
CR 18-069: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.008 Note
CSB 2.62 Addition of para-chloroisobutyryl fentanyl to schedule I. Section
961.14 (2) (nd) 16s., Stats., is created to read:
CSB 2.008 Note
961.14 (2) (nd) 16s. Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2018 No. 747, eff. 3-12-18;
CR 18-070: cr.
Register June 2019 No. 762, eff. 7-1-19.
CSB 2.008 Note
CSB 2.63 Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I. Section
961.14 (4) (tb) 44.,
45.,
46.,
47., and
48., Stats., are created to read:
CSB 2.008 Note
961.14 (4) (tb) 44. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201.
CSB 2.008 Note
45. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, commonly known as 5F-AB-PINACA.
CSB 2.008 Note
46. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA.
CSB 2.008 Note
47. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA.
CSB 2.008 Note
48. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2018 No. 747, eff. 3-12-18; cr. Affirmative action order under s.
961.11 (4), Stats.,
Register August 2018 No. 752, eff. 8-13-18; correction made under s.
35.17, Stats.,
Register August 2018 No. 752;
CR 19-010: cr.
Register June 2020 No. 774, eff. 7-1-20; correction made under s.
35.17, Stats.,
Register June 2021 No. 786.
CSB 2.008 Note
CSB 2.64 Addition of N-Ethylpentylone to schedule I. Section
961.14 (7) (L) 34., Stats., is created to read:
CSB 2.008 Note
961.14 (7) (L) 34. N-Ethylpentylone, commonly known as ephylone.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register October 2018 No. 754, eff. 10-8-18;
CR 19-011: cr.
Register June 2020 No. 774, eff. 7-1-20.
CSB 2.008 Note
CSB 2.65 Addition of approved cannabidiol drugs to schedule V. Section
961.22 (7), Stats., is created to read:
CSB 2.008 Note
961.22 (7) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4g), Stats.,
Register October 2018 No. 754, eff. 10-15-18;
CR 19-012: cr.
Register June 2020 No. 774, eff. 7-1-20.
CSB 2.008 Note
CSB 2.66 Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I. Section
961.14 (4) (tb),
49.,
50.,
51.,
52., and
53., Stats., are created to read:
CSB 2.008 Note
961.14 (4) (tb) 49. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.
CSB 2.008 Note
50. Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.
CSB 2.008 Note
51. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).
CSB 2.008 Note
52. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.
CSB 2.008 Note
53. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register March 2019 No. 759, eff. 3-11-19;
CR 20-048: cr.
Register June 2021 No. 786, eff. 7-1-21.
CSB 2.008 Note
CSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section
961.20 (2) (ap) and
(2m) (g), Stats., are created to read:
CSB 2.008 Note
961.20 (2) (ap) Brexanolone;
CSB 2.008 Note
(2m) (g) Solriamfetol.
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register July 2019 No. 763, eff. 7-22-19;
CR 20-049: cr.
Register June 2021 No. 786, eff. 7-1-21; correction in (2) (ap) made under s.
35.17, Stats.,
Register June 2021 No. 785.
CSB 2.008 Note
CSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section
961.14 (7) (L) 35. to
40., Stats., is created to read: